- English
- PDF
- Available on iOS & Android
About this book
Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Half-title page
- Title page
- Copyright page
- Contents
- Foreword
- Introduction
- 1. The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2. Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3. Initiating Clozapine
- 4. Discontinuing Clozapine and Management of Cholinergic Rebound
- 5. Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6. Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7. Managing Constipation
- 8. Managing Sedation, Orthostasis and Tachycardia
- 9. Managing Sialorrhea
- 10. Managing Seizure Risk and Stuttering
- 11. Managing Metabolic Adverse Effects
- 12. Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13. Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia a d Obsessive Compulsive Disorder
- 14. Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15. Special Topics: Child and Adolescent Patients, Elderly Patients, Patients with Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index